Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Apr;117(7):1535–1543. doi: 10.1111/j.1476-5381.1996.tb15318.x

Unusual alpha-adrenoceptor subtype in canine saphenous vein: comparison to mesenteric vein.

E E Daniel 1, A M Low 1, V Gaspar 1, H Lu-Chao 1, J Green 1, J Akrong 1, S Duerksen 1, C Soyka 1, C K Chen 1, J Boyd 1, C Y Kwan 1
PMCID: PMC1909456  PMID: 8730751

Abstract

1. We investigated the nature of the adrenoceptors in the dog saphenous vein (DSV) and dog mesenteric vein (DMV) to determine the nature of the unexpected interactions of phenylephrine and methoxamine with rauwolscine in the DSV, i.e. the ability of the putative alpha 2-adrenoceptor antagonist to inhibit competitively contractions to these alpha 1-agonists. Radioligand binding studies were performed in parallel with contractility studies. 2. Functionally, in the DSV, phenylephrine and methoxamine-induced, contractions were antagonized by rauwolscine with Schild slopes of -0.52 and -0.46, respectively and apparent pA2 values of 8.5 and 9.2, respectively. Such antagonism was not observed in the DMV. In the DSV, prazosin competes for [3H]-rauwolscine binding sites with a high and a low affinity binding site (Ki of 1.49 +/- 0.65 and 94.7 +/- 51 microM, n = 6, respectively). 3. Pretreatment with 100 microM chloroethylclonidine (CEC) for 15 min abolished [3H]-prazosin binding in microsomes from both veins and reduced binding (Bmax) of [3H]-rauwolscine in microsomes by 55.1 +/- 0.8% (n = 3) in the DSV but did not affect the Bmax in the DMV. CEC pretreatment in the venular rings denuded of endothelium caused persistent contraction in the DSV but not in the DMV. In the DSV, CEC appeared to interact with a single [3H]-rauwolscine binding site. In both the DSV and the DMV, CEC (100 microM) caused a significant shift in the EC50 values for phenylephrine and methoxamine. Maximum responses in the DMV were significantly attenuated while those in the DSV were unaffected when total tension was considered. 4. Studies of the functional interactions of the DSV and the DMV with WB 4101 or 5-methylurapidil (5-MU) suggested the presence of alpha 1D-adrenoceptors in the DSV and alpha 1A-adrenoceptors in the DMV. The receptors inactivated by CEC in the DMV and DSV may represent some or all of the receptors with properties of alpha 1D and alpha 1A-receptors present in the two veins. Studies of radioligand binding interactions of these two antagonists with [3H]-prazosin, were consistent with the presence of some alpha 1D-receptors in DSV and alpha 1A-receptors in DMV. These findings raise questions about the selectivity of CEC in differentiating alpha 1-adrenoceptor subtypes. 5. B-HT 920 caused contractions in the DSV smaller than those to the alpha 1-agonists but the maximum was not affected by CEC pretreatment. The EC50 values were shifted to the left after CEC. In radioligand binding studies, B-HT 920 competition for [3H]-rauwolscine binding was not significantly affected by CEC pretreatment. 6. These results suggest the presence of unusual alpha-adrenoceptors in the DSV. In addition to alpha 2-adrenoceptors, receptors recognizing rauwolscine as well as prazosin, WB 4101, phenylephrine and methoxamine and susceptible to inactivation by CEC are present. They appear to be, in part, unusual alpha 1D-adrenoceptors.

Full text

PDF
1535

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agrawal D. K., Daniel E. E. Agonists interaction with radiolabeled alpha-adrenoceptor antagonists binding sites in rat mesenteric artery. J Cardiovasc Pharmacol. 1985;7 (Suppl 6):S66–S75. doi: 10.1097/00005344-198500076-00012. [DOI] [PubMed] [Google Scholar]
  2. Bylund D. B. Subtypes of alpha 1- and alpha 2-adrenergic receptors. FASEB J. 1992 Feb 1;6(3):832–839. doi: 10.1096/fasebj.6.3.1346768. [DOI] [PubMed] [Google Scholar]
  3. Daniel E. E., Gaspar V., Berezin I., Kwan C. Y. Characterization of alpha 2 adrenoceptors and other adrenoceptors in membranes isolated from dog mesenteric nerve axons. J Pharmacol Exp Ther. 1995 Nov;275(2):978–986. [PubMed] [Google Scholar]
  4. Daniel E. E., Shi A. G., Wang Z. L., Guan Y. Y., Hoo K., Cragoe E. J., Kwan C. Y. Alpha-adrenoceptors in vascular smooth muscle: all is not well. Blood Vessels. 1991;28(1-3):104–114. doi: 10.1159/000158849. [DOI] [PubMed] [Google Scholar]
  5. Han C., Abel P. W., Minneman K. P. Heterogeneity of alpha 1-adrenergic receptors revealed by chlorethylclonidine. Mol Pharmacol. 1987 Oct;32(4):505–510. [PubMed] [Google Scholar]
  6. Hicks P. E., Barras M., Herman G., Mauduit P., Armstrong J. M., Rossignol B. Alpha-adrenoceptor subtypes in dog saphenous vein that mediate contraction and inositol phosphate production. Br J Pharmacol. 1991 Jan;102(1):151–161. doi: 10.1111/j.1476-5381.1991.tb12146.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kwan C. Y., Triggle C. R., Grover A. K., Lee R. M., Daniel E. E. An analytical approach to the preparation and characterization of subcellular membranes from canine mesenteric arteries. Prep Biochem. 1983;13(4):275–314. doi: 10.1080/00327488308068175. [DOI] [PubMed] [Google Scholar]
  8. Low A. M., Bowdish D. M., Prashad T. R., Gaspar V. Interactions of chloroethylclonidine with rauwolscine- and prazosin-sensitive adrenoceptors in dog saphenous vein. Br J Pharmacol. 1994 Dec;113(4):1263–1268. doi: 10.1111/j.1476-5381.1994.tb17134.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. MacKinnon A. C., Spedding M., Brown C. M. Alpha 2-adrenoceptors: more subtypes but fewer functional differences. Trends Pharmacol Sci. 1994 Apr;15(4):119–123. doi: 10.1016/0165-6147(94)90048-5. [DOI] [PubMed] [Google Scholar]
  10. McPherson G. A. A practical computer-based approach to the analysis of radioligand binding experiments. Comput Programs Biomed. 1983 Aug-Oct;17(1-2):107–113. doi: 10.1016/0010-468x(83)90031-4. [DOI] [PubMed] [Google Scholar]
  11. Michel M. C., Kerker J., Branchek T. A., Forray C. Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes. Mol Pharmacol. 1993 Dec;44(6):1165–1170. [PubMed] [Google Scholar]
  12. Minneman K. P., Theroux T. L., Hollinger S., Han C., Esbenshade T. A. Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929–936. [PubMed] [Google Scholar]
  13. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  14. Perez D. M., Piascik M. T., Malik N., Gaivin R., Graham R. M. Cloning, expression, and tissue distribution of the rat homolog of the bovine alpha 1C-adrenergic receptor provide evidence for its classification as the alpha 1A subtype. Mol Pharmacol. 1994 Nov;46(5):823–831. [PubMed] [Google Scholar]
  15. Ruffolo R. R., Jr, Nichols A. J., Stadel J. M., Hieble J. P. Structure and function of alpha-adrenoceptors. Pharmacol Rev. 1991 Dec;43(4):475–505. [PubMed] [Google Scholar]
  16. Shi A. G., Ahmad S., Kwan C. Y., Daniel E. E. Alpha-adrenoceptors in dog mesenteric vessels--subcellular distribution and number of [3H]prazosin and [3H]rauwolscine binding sites. J Cardiovasc Pharmacol. 1990 Apr;15(4):515–526. doi: 10.1097/00005344-199004000-00001. [DOI] [PubMed] [Google Scholar]
  17. Shi A. G., Ahmad S., Kwan C. Y., Daniel E. E. Characterization of alpha-adrenoceptor subtypes by [3H]prazosin and [3H]rauwolscine binding to canine venous smooth muscle membranes. Can J Physiol Pharmacol. 1989 Sep;67(9):1067–1073. doi: 10.1139/y89-169. [DOI] [PubMed] [Google Scholar]
  18. Shi A. G., Kwan C. Y., Daniel E. E. Relation between density (maximum binding) of alpha adrenoceptor binding sites and contractile response in four canine vascular tissues. J Pharmacol Exp Ther. 1989 Sep;250(3):1119–1124. [PubMed] [Google Scholar]
  19. Shimamoto H., Bourreau J. P., Kwan C. Y., Daniel E. E. Amplification of alpha adrenergic vasoconstriction in canine isolated mesenteric artery and vein. J Pharmacol Exp Ther. 1992 Mar;260(3):1119–1127. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES